中国输血杂志2026，Vol.39Issue(6)：784-788,5.DOI:10.13303/j.cjbt.issn.1004-549x.2026.06.012
新型抗-CD38迈泽妥单抗对输血前检测试验的干扰及处理措施
Interference and treatment strategy of a novel anti-CD38 antibody—mezagitamab in pre-transfusion test
摘要
Abstract
Objective To investigate the specific interference of the novel anti-CD38 antibody mezagitamab in pre-transfusion testing,establish an immunomagnetic bead pre-treatment method to eliminate it,and evaluate its impact on other blood group systems and clinical timeliness,thereby providing experimental evidence and a solution for safe transfusion.Methods MOLP8 cellular protein coated immunomagnetic beads were prepared.Unexpected antibody screening was per-formed on simulated samples with different mezagitamab concentrations to verify the interference elimination effect.The im-pact of immunomagnetic bead adsorption of mezagitamab on antigenantibody reactions in other blood group systems was as-sessed,and the duration of the interferenceeliminating effect was studied.Results MOLP8-coated immunomagnetic beads were successfully prepared,which effectively eliminated mezagitamab interference at different concentrations without affect-ing other blood group detection,with a stable effect for 2 weeks.Conclusion MOLP8 cellular protein-coated immunomag-netic beads efficiently and specifically eliminate mezagitamab-induced pre-transfusion testing interference without affecting other blood groups,providing a theoretical basis for safe transfusion in patients receiving mezagitamab therapy.关键词
迈泽妥单抗/CD38/输血前/干扰/消除策略Key words
mezagitamab/CD38/pre-transfusion testing/interference/elimination strategy分类
医药卫生引用本文复制引用
魏华,任冬霞,赵静雅,穆士杰,杨龙飞..新型抗-CD38迈泽妥单抗对输血前检测试验的干扰及处理措施[J].中国输血杂志,2026,39(6):784-788,5.基金项目
西安市科技计划项目(25YXYJYB00145),唐都医院学科助推计划(2024JSYX018) （25YXYJYB00145）
